Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05VAE
|
||||
| Former ID |
DIB013659
|
||||
| Drug Name |
Posiphen R-phenserine
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Phase 1 | [550986] | ||
| Company |
Qr pharma
|
||||
| Target and Pathway | |||||
| Target(s) | Alpha-synuclein | Target Info | Modulator | [550986], [550987] | |
| KEGG Pathway | Alzheimer's disease | ||||
| Parkinson's disease | |||||
| NetPath Pathway | Leptin Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| PANTHER Pathway | Parkinson disease | ||||
| Pathway Interaction Database | Alpha-synuclein signaling | ||||
| Reactome | Amyloid formation | ||||
| References | |||||
| Ref 550986 | The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5??ntranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression. Parkinson's Disease Volume 2012 (2012), Article ID 142372, Page(13). | ||||
| Ref 550987 | The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5??ntranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression. Parkinson's Disease Volume 2012 (2012), Article ID 142372, Page(13). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.